Equol and Resveratrol Improve Bone Turnover Biomarkers in Postmenopausal Women: A Clinical Trial

Int J Mol Sci. 2023 Jul 27;24(15):12063. doi: 10.3390/ijms241512063.


Estrogen deficiency is a major cause of loss of postmenopausal bone mineral density (BMD). This study aimed to evaluate the effects of equol and resveratrol on bone turnover biomarkers in postmenopausal women. Sixty healthy postmenopausal women were randomly assigned to receive 200 mg fermented soy containing 10 mg equol and 25 mg resveratrol or a placebo for 12 months. Whole-body BMD and bone turnover biomarkers, such as deoxypyridinoline (DPD), tartrate-resistant acid phosphatase 5b (TRACP-5b), osteocalcin, and bone-specific alkaline phosphatase (BAP), were measured at baseline and after 12 months of treatment. At the end of treatment, DPD, osteocalcin, and BAP significantly improved in the active group (p < 0.0001 for all) compared to the placebo group. Conversely, TRACP-5b levels were unaffected by supplementation (p = 0.051). Statistically significant changes in the concentrations of DPD (p < 0.0001), osteocalcin (p = 0.0001), and BAP (p < 0.0001) compared to baseline were also identified. Overall, the intervention significantly increased BMD measured in the whole body (p = 0.0220) compared with the placebo. These data indicate that the combination of equol and resveratrol may positively modulate bone turnover biomarkers and BMD, representing a potential approach to prevent age-related bone loss in postmenopausal women.

Keywords: bone metabolism markers; bone mineral density; equol; menopause; resveratrol.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Alkaline Phosphatase / therapeutic use
  • Biomarkers
  • Bone Density
  • Bone Remodeling
  • Equol / pharmacology
  • Female
  • Humans
  • Osteocalcin
  • Osteoporosis, Postmenopausal* / drug therapy
  • Postmenopause*
  • Resveratrol / pharmacology
  • Resveratrol / therapeutic use
  • Tartrate-Resistant Acid Phosphatase


  • Equol
  • Resveratrol
  • Tartrate-Resistant Acid Phosphatase
  • Osteocalcin
  • Alkaline Phosphatase
  • Biomarkers

Grants and funding

This study was not supported by any industrial funds. PaladinPharma S.p.A. only provided the placebo and the active treatment. This company had no influence on the study design; in the collection, analysis or interpretation of data; or in the decision to submit the article for publication.